Metabolic perturbations sensitize triple-negative breast cancers to apoptosis induced by BH3 mimetics.

Science Signaling
Veerle W DanielsAnthony Letai

Abstract

Cancer cells have differential metabolic dependencies compared to their nonmalignant counterparts. However, few metabolism-targeting compounds have been successful in clinical trials. Here, we investigated the metabolic vulnerabilities of triple-negative breast cancer (TNBC), particularly those metabolic perturbations that increased mitochondrial apoptotic priming and sensitivity to BH3 mimetics (drugs that antagonize antiapoptotic proteins). We used high-throughput dynamic BH3 profiling (HT-DBP) to screen a library of metabolism-perturbing small molecules, which revealed inhibitors of the enzyme nicotinamide phosphoribosyltransferase (NAMPT) as top candidates. In some TNBC cells but not in nonmalignant cells, NAMPT inhibitors increased overall apoptotic priming and induced dependencies on specific antiapoptotic BCL-2 family members. Treatment of TNBC cells with NAMPT inhibitors sensitized them to subsequent treatment with BH3 mimetics. The combination of a NAMPT inhibitor (FK866) and an MCL-1 antagonist (S63845) reduced tumor growth in a TNBC patient-derived xenograft model in vivo. We found that NAMPT inhibition reduced NAD+ concentrations below a critical threshold that resulted in depletion of adenine, which was the metabol...Continue Reading

References

Dec 11, 1999·Nucleic Acids Research·M Kanehisa, S Goto
Jan 5, 2007·Nucleic Acids Research·David S WishartLori Querengesser
Dec 7, 2007·Blood·Victoria Del Gaizo MooreAnthony Letai
Feb 6, 2009·Journal of Cell Science·Joslyn K Brunelle, Anthony Letai
Apr 4, 2009·Nature Reviews. Cancer·Mark S CraggClare L Scott
Jun 16, 2009·Toxicology in Vitro : an International Journal Published in Association with BIBRA·Yang WuStephen P Adams
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leena GandhiCharles M Rudin
Mar 8, 2011·Cell·Douglas Hanahan, Robert A Weinberg
Aug 31, 2012·EMBO Molecular Medicine·Ilirjana BajramiAlan Ashworth
Sep 29, 2012·Nature Reviews. Cancer·Alberto ChiarugiMathias Ziegler
Mar 9, 2013·Cell Death & Disease·Y ZhaoM Tan
Apr 24, 2013·Methods : a Companion to Methods in Enzymology·Jeremy Ryan, Anthony Letai
Sep 13, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Claudia C S ChiniEduardo N Chini
Mar 31, 2015·The Cancer Journal·Melissa M Keenan, Jen-Tsan Chi
Apr 4, 2015·Critical Reviews in Biochemistry and Molecular Biology·Andrey NikiforovMathias Ziegler
Jul 29, 2015·Nature Reviews. Endocrinology·Antje GartenWieland Kiess
Feb 11, 2016·World Journal of Clinical Oncology·Jing-Pei LongFeng Zhang
Mar 5, 2016·Molecular Cell·Patrick D Bhola, Anthony Letai
Nov 3, 2016·Nature Reviews. Clinical Oncology·Ubaldo E Martinez-OutschoornMichael P Lisanti
Dec 29, 2016·Trends in Biochemical Sciences·Anthony M Pedley, Stephen J Benkovic
Aug 2, 2017·Biochemical and Biophysical Research Communications·Jun GuoTzu-Hsuan Huang
Nov 2, 2017·Cell Reports·Gerta HoxhajBrendan D Manning
Nov 16, 2017·Nucleic Acids Research·David S WishartAugustin Scalbert
Dec 12, 2018·Cancer Cell·Delphine MerinoAndreas Strasser
Jan 12, 2019·Frontiers in Oncology·Keisuke YakuTakashi Nakagawa
Mar 13, 2019·ELife·Benoît PinsonBertrand Daignan-Fornier

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Breast Cancer Triple-N

Breast cancer cells have receptors for estrogen, progesterone, HER2 receptors (also called ERBB2). Triple-negative breast cancers do not have any of these receptors. Here are the latest discoveries pertaining to triple-negative breast cancers.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis